In adults with ANCA-associated vasculitis (AAV), the amount of TWEAK protein in urine was about 50% as high when…
Articles by Margarida Maia, PhD
Vertex Pharmaceuticals has signed a license agreement with Ono Pharmaceutical to develop and market povetacicept — a B-cell-targeting…
Updated treatment guidelines from the British Society for Rheumatology favor rituximab over cyclophosphamide for active, relapsing ANCA-associated vasculitis…
Treatments for ANCA-associated vasculitis (AAV) have improved over time, but many patients still develop permanent organ damage, even though…
People diagnosed with ANCA-associated vasculitis (AAV) at age 75 or older may show more inflammation, higher rates of kidney…
An imaging test that can make detailed pictures of the heart can detect scar tissue buildup in the heart muscle…
Infections are a leading cause of early death in adults with ANCA-associated vasculitis (AAV), being most common in the…
Adults with active eosinophilic granulomatosis with polyangiitis (EGPA), a rare type of ANCA-associated vasculitis (AAV), report improvements in health-related…
Microscopic polyangiitis (MPA) patients with high blood levels of the inflammatory protein interferon gamma (IFN-gamma) at the onset of their…
Fasenra (benralizumab) and Nucala (mepolizumab) appear to be equally safe and effective in helping adults with eosinophilic granulomatosis…